Royalty Pharma

Live  

Royalty Pharma is a leading player in the biopharmaceutical industry, specializing in acquiring and managing revenue-producing intellectual property associated with pharmaceutical products. Founded in 1996, the company primarily focuses on purchasing royalty interests and product rights from biotechnology and pharmaceutical companies.
Royalty Pharma’s business model allows it to leverage existing drugs that are already on the market or in late-stage development, enabling it to generate revenue without the substantial costs and risks associated with drug development. The company has a diversified portfolio that includes royalties from a variety of therapeutic areas, such as oncology, neurology, and rare diseases.
In addition to its royalty acquisition activities, Royalty Pharma is engaged in partnerships with biopharmaceutical firms, providing them with upfront capital in exchange for a share of future revenues. The company is publicly traded and has grown significantly over the years through strategic acquisitions, strong financial management, and a focus on high-quality assets.
Royalty Pharma emphasizes its commitment to scientific innovation and the efficient delivery of healthcare solutions, while also maintaining a strong network of relationships within the industry, including collaborations with inventors and research institutions. The company is known for its financial strength, which allows it to pursue new opportunities in an evolving market.

Um95YWx0eS BQaGFybWEg aXMgYSBjb2 1wYW55IHRo YXQgaGVscH MgZGV2ZWxv cCBhbmQgc3 VwcG9ydCBt ZWRpY2luZX MuIEltYWdp bmUgaWYgdG hlcmUgd2Vy ZSBhIHJlYW xseSBjb29s IHRveSB0aG F0IG5lZWRl ZCBtb25leS B0byBiZSBk ZXNpZ25lZC BhbmQgbWFk ZS4gUm95YW x0eSBQaGFy bWEgZG9lcy Bzb21ldGhp bmcgc2ltaW xhciBidXQg Zm9yIG1lZG ljaW5lcyB0 aGF0IGhlbH AgcGVvcGxl IGZlZWwgYm V0dGVyLiBX aGVuIGEgbm V3IG1lZGlj aW5lIGlzIG NyZWF0ZWQs IGl0IHVzdW FsbHkgY29z dHMgYSBsb3 Qgb2YgbW9u ZXkgdG8gZG V2ZWxvcCwg d2hpY2ggY2 FuIGluY2x1 ZGUgcmVzZW FyY2gsIHRl c3RpbmcsIG FuZCBnZXR0 aW5nIGFwcH JvdmFsIGZy b20gaGVhbH RoIGF1dGhv cml0aWVzLj xicj5Ob3cs IGhlcmXigJ lzIGhvdyBS b3lhbHR5IF BoYXJtYSBt YWtlcyBtb2 5leTogdGhl eSBpbnZlc3 QgbW9uZXkg aW4gdGhlc2 UgbmV3IG1l ZGljaW5lcy BlYXJseSBv bi4gV2hlbi B0aGUgbWVk aWNpbmUgYm Vjb21lcyBz dWNjZXNzZn VsIGFuZCBz b2xkIHRvIH Blb3BsZSwg Um95YWx0eS BQaGFybWEg ZWFybnMgYS BwZXJjZW50 YWdlIG9mIH RoZSBtb25l eSBtYWRlIG Zyb20gdGhv c2Ugc2FsZX MuIEl04oCZ cyBsaWtlIG lmIHRoZXkg aGVscGVkIH NvbWVvbmUg Y3JlYXRlIG EgcG9wdWxh ciB0b3ksIH RoZXkgd291 bGQgZ2V0IG EgbGl0dGxl IGJpdCBvZi Btb25leSBl dmVyeSB0aW 1lIHRoYXQg dG95IHdhcy Bzb2xkLjxi cj5BcyBmb3 Igd2h5IFJv eWFsdHkgUG hhcm1hIGlz IHN1Y2Nlc3 NmdWwgYW5k IGxpa2VseS B0byBzdGF5 IHN1Y2Nlc3 NmdWwsIHRo ZXJlIGFyZS BhIGZldyBy ZWFzb25zLi BGaXJzdCwg dGhleSBwaW NrIHJlYWxs eSBwcm9taX NpbmcgbWVk aWNpbmVzIH RvIGludmVz dCBpbiwgd2 hpY2ggbWVh bnMgdGhleS BvZnRlbiBj aG9vc2UgdG hvc2UgdGhh dCBoYXZlIG EgZ29vZCBj aGFuY2UgdG 8gaGVscCBs b3RzIG9mIH Blb3BsZSBh bmQgbWFrZS Btb25leS4g U2Vjb25kLC B0aGV5IHdv cmsgd2l0aC BtYW55IGRp ZmZlcmVudC BraW5kcyBv ZiBtZWRpY2 luZXMsIHNv IHRoZXkgZG 9u4oCZdCBq dXN0IHJlbH kgb24gb25l LiBUaGlzIH ZhcmlldHkg aGVscHMgcH JvdGVjdCB0 aGVtIGlmIG 9uZSBtZWRp Y2luZSBkb2 VzbuKAmXQg ZG8gd2VsbC 4gRmluYWxs eSwgd2l0aC BtYW55IG5l dyBkaXNlYX NlcyB0aGF0 IG5lZWQgdH JlYXRtZW50 cyBhbmQgY2 9uc3RhbnQg cmVzZWFyY2 ggaGFwcGVu aW5nLCB0aG VyZSB3aWxs IGFsd2F5cy BiZSBuZXcg b3Bwb3J0dW 5pdGllcyBm b3IgUm95YW x0eSBQaGFy bWEgdG8gaW 52ZXN0IGlu IGFuZCBtYW tlIG1vbmV5 IGZyb20uIF RoYXTigJlz IHdoeSBtYW 55IHBlb3Bs ZSBiZWxpZX ZlIHRoZXkg d2lsbCBjb2 50aW51ZSB0 byBiZSBzdW NjZXNzZnVs IGluIHRoZS BmdXR1cmUh PGJyPg==

Um95YWx0eS BQaGFybWEg aXMgbm90YW JsZSBmb3Ig aXRzIHVuaX F1ZSBidXNp bmVzcyBtb2 RlbCBjZW50 ZXJlZCBhcm 91bmQgYWNx dWlyaW5nIG FuZCBtYW5h Z2luZyByZX ZlbnVlLWdl bmVyYXRpbm cgcGhhcm1h Y2V1dGljYW wgcm95YWx0 aWVzLiBUaG UgY29tcGFu eSBmb2N1c2 VzIG9uIGZ1 bmRpbmcgdG hlIGRldmVs b3BtZW50IG 9mIG5ldyBk cnVncyBieS BwdXJjaGFz aW5nIHJveW FsdHkgc3Ry ZWFtcyBmcm 9tIGRldmVs b3BlcnMgYW 5kIGNvbXBh bmllcyB0aG F0IGJyaW5n IGlubm92YX RpdmUgdGhl cmFwaWVzIH RvIHRoZSBt YXJrZXQuIF RoaXMgYWxs b3dzIHRoZW 0gdG8gZ2Vu ZXJhdGUgaW 5jb21lIHdp dGhvdXQgdG hlIHJpc2tz IGFzc29jaW F0ZWQgd2l0 aCBkcnVnIG RldmVsb3Bt ZW50LCBhcy B0aGV5IGRv IG5vdCBlbm dhZ2UgZGly ZWN0bHkgaW 4gcmVzZWFy Y2ggYW5kIG RldmVsb3Bt ZW50Ljxicj 5BZGRpdGlv bmFsbHksIF JveWFsdHkg UGhhcm1hIG hhcyBhIGRp dmVyc2UgcG 9ydGZvbGlv IHRoYXQgZW 5jb21wYXNz ZXMgdmFyaW 91cyB0aGVy YXBldXRpYy BhcmVhcywg aW5jbHVkaW 5nIG9uY29s b2d5LCBpbW 11bm9sb2d5 LCBhbmQgaW 5mZWN0aW91 cyBkaXNlYX Nlcywgd2hp Y2ggZW5oYW 5jZXMgaXRz IHJpc2sgZG l2ZXJzaWZp Y2F0aW9uLi BUaGUgY29t cGFueSBhbH NvIHBsYXlz IGEgcm9sZS BpbiBlbmFi bGluZyBiaW 90ZWNoIGFu ZCBwaGFybW FjZXV0aWNh bCBjb21wYW 5pZXMgdG8g YWNjZXNzIG NhcGl0YWws IHRodXMgZm FjaWxpdGF0 aW5nIHRoZS BhZHZhbmNl bWVudCBvZi BtZWRpY2Fs IHJlc2Vhcm NoIGFuZCBp bm5vdmF0aW 9uLjxicj5G dXJ0aGVybW 9yZSwgUm95 YWx0eSBQaG FybWEgaXMg cHVibGljbH kgdHJhZGVk IGFuZCBpcy Brbm93biBm b3IgaXRzIG ZpbmFuY2lh bCBzdHJlbm d0aCwgbWFr aW5nIGl0IG FuIGF0dHJh Y3RpdmUgaW 52ZXN0bWVu dCBmb3IgdG hvc2UgbG9v a2luZyBmb3 IgZXhwb3N1 cmUgdG8gdG hlIHBoYXJt YWNldXRpY2 FsIGluZHVz dHJ5IHdpdG hvdXQgdGhl IHZvbGF0aW xpdHkgdHlw aWNhbGx5IG Fzc29jaWF0 ZWQgd2l0aC BkcnVnIGRl dmVsb3BtZW 50IHN0b2Nr cy4gSXRzIG 1vZGVsIGhh cyBnYWluZW QgYXR0ZW50 aW9uIGFzIH RoZSBiaW9w aGFybWFjZX V0aWNhbCBz ZWN0b3IgY2 9udGludWVz IHRvIGV2b2 x2ZSwgaGln aGxpZ2h0aW 5nIHRoZSBp bXBvcnRhbm NlIG9mIGFs dGVybmF0aX ZlIGZ1bmRp bmcgbWVjaG FuaXNtcyB3 aXRoaW4gdG hlIGluZHVz dHJ5Ljxicj 4=

Um95YWx0eS BQaGFybWEg aXMgYSBiaW 9waGFybWFj ZXV0aWNhbC Bjb21wYW55 IHRoYXQgZm 9jdXNlcyBv biBhY3F1aX JpbmcgYW5k IG1hbmFnaW 5nIHJldmVu dWUtZ2VuZX JhdGluZyBw aGFybWFjZX V0aWNhbCBh bmQgYmlvdG VjaG5vbG9n eSBhc3NldH MuIEl0cyBw cmltYXJ5IG J1c2luZXNz IG1vZGVsIG ludm9sdmVz IHB1cmNoYX Npbmcgcm95 YWx0eSBpbn RlcmVzdHMg YW5kIHVsdH JhLXJhcmUg ZGlzZWFzZS Bhc3NldHMg ZnJvbSBvdG hlciBjb21w YW5pZXMuIF RoaXMgYWxs b3dzIHRoZW 0gdG8gZ2Vu ZXJhdGUgcm V2ZW51ZSBi YXNlZCBvbi B0aGUgc2Fs ZXMgb2YgdG hlc2UgZHJ1 Z3Mgd2l0aG 91dCB0aGUg YXNzb2NpYX RlZCBjb3N0 cyBvZiByZX NlYXJjaCBh bmQgZGV2ZW xvcG1lbnQs IG1hbnVmYW N0dXJpbmcs IG9yIG1hcm tldGluZy48 YnI+VGhleS B0eXBpY2Fs bHkgZW50ZX IgaW50byBh Z3JlZW1lbn RzIHdpdGgg ZHJ1ZyBkZX ZlbG9wZXJz LCBpbmNsdW RpbmcgbWFq b3IgcGhhcm 1hY2V1dGlj YWwgY29tcG FuaWVzIGFu ZCBzbWFsbG VyIGJpb3Rl Y2ggZmlybX MsIHRvIGFj cXVpcmUgYS BwZXJjZW50 YWdlIG9mIH RoZSBmdXR1 cmUgc2FsZX Mgb2YgdGhl aXIgcHJvZH VjdHMuIFRo aXMgY2FuIG luY2x1ZGUg ZXN0YWJsaX NoZWQgYmxv Y2tidXN0ZX IgZHJ1Z3Mg YXMgd2VsbC BhcyBlbWVy Z2luZyB0aG VyYXBpZXMg aW4gdmFyaW 91cyBzdGFn ZXMgb2YgZG V2ZWxvcG1l bnQuIEJ5IG RpdmVyc2lm eWluZyB0aG VpciBwb3J0 Zm9saW8gYW Nyb3NzIG51 bWVyb3VzIH Byb2R1Y3Rz IGFuZCB0aG VyYXBldXRp YyBhcmVhcy wgUm95YWx0 eSBQaGFybW EgbWl0aWdh dGVzIHJpc2 sgYW5kIGNh cGl0YWxpem VzIG9uIHRo ZSBncm93dG ggcG90ZW50 aWFsIG9mIG lubm92YXRp dmUgdHJlYX RtZW50cy48 YnI+QWRkaX Rpb25hbGx5 LCB0aGUgY2 9tcGFueSBt YXkgYWxzby BlbmdhZ2Ug aW4gZmluYW 5jaW5nIGFy cmFuZ2VtZW 50cywgc3Vj aCBhcyBzdH J1Y3R1cmlu ZyBjb250aW 5nZW50IHBh eW1lbnRzIG Jhc2VkIG9u IGZ1dHVyZS BzYWxlcyBt aWxlc3Rvbm VzLiBCeSBs ZXZlcmFnaW 5nIHRoZWly IGV4cGVydG lzZSBpbiB0 aGUgcGhhcm 1hY2V1dGlj YWwgbWFya2 V0IGFuZCBj YXBpdGFsaX ppbmcgb24g YXR0cmFjdG l2ZSBpbnZl c3RtZW50IG 9wcG9ydHVu aXRpZXMsIF JveWFsdHkg UGhhcm1hIG FpbXMgdG8g cHJvdmlkZS ByZXR1cm5z IHRvIGl0cy BpbnZlc3Rv cnMgd2hpbG Ugc3VwcG9y dGluZyB0aG UgY29udGlu dWVkIGRldm Vsb3BtZW50 IG9mIGltcG 9ydGFudCBo ZWFsdGhjYX JlIHNvbHV0 aW9ucy48Yn I+

AI can potentially pose a threat to Royalty Pharma’s products, services, and competitive positioning in various ways, although the extent of these threats may vary based on how the company adapts to advancements in technology.
1. Substitution: AI may enable the development of new therapies or drug discovery methods that could provide competitive alternatives to the products that Royalty Pharma has backed. If AI accelerates the creation of novel therapeutics or enhances the effectiveness of existing treatments, these innovations could compete directly with the portfolio of drugs for which Royalty Pharma holds royalties.
2. Disintermediation: AI technology might streamline drug development processes and lead to changes in how pharmaceuticals are commercialized. For example, the rise of direct-to-consumer models and AI-driven platforms could reduce the need for traditional intermediaries, potentially impacting Royalty Pharma’s business model, especially if newer companies bypass traditional royalty structures altogether.
3. Margin Pressure: The integration of AI into various aspects of pharmaceutical development and marketing can lead to increased efficiency, reduced costs, and enhanced productivity for competitors. If rivals who adopt AI technologies succeed in lowering their operating costs or improving their product offerings, this could exert margin pressure on Royalty Pharma, especially if the company is slower to adapt to these technological advancements.
Overall, while AI presents certain risks to Royalty Pharma, it also offers opportunities for enhanced efficiencies and improved decisiomaking in drug investment and royalty management. How the company responds to these AI-related challenges will be crucial in determining its competitive positioning in the healthcare sector.

Royalty Pharma’s earnings, cash flow, and valuation are particularly sensitive to changes in interest rates due to several factors:
1. Cost of Capital: Higher interest rates increase the cost of debt. If Royalty Pharma finances acquisitions or operations through debt, rising rates can lead to increased interest expenses, thereby reducing net earnings and cash flow.
2. Discount Rate: Valuations of companies, especially those reliant on future cash flows, are sensitive to the discount rate used in discounted cash flow (DCF) models. As interest rates rise, the discount rate typically increases, which can lower the present value of future cash flows, negatively impacting the valuation of Royalty Pharma.
3. Opportunity Cost: As interest rates rise, investors may seek safer investments, such as bonds, which become more attractive compared to equities. This shift can lead to a decrease in demand for Royalty Pharma’s stock, affecting its market valuation.
4. Pharmaceutical Industry Dynamics: Royalty Pharma’s business model relies on securing royalties from pharmaceutical products. If interest rates increase, it may result in costlier financing for research and development in the pharmaceutical industry, potentially delaying or reducing the number of successful drug developments. This could ultimately impact the cash flows derived from royalty agreements.
5. Judgment on Future Growth: Higher interest rates may slow overall economic growth, which can impact healthcare spending and the demand for pharmaceuticals. If public and private payers adjust their spending in response to economic conditions, this could directly affect Royalty Pharma’s revenues.
In summary, Royalty Pharma’s financial metrics and valuation are closely linked to interest rates through mechanisms such as cost of capital, discount rates, investor behavior, and the broader economic environment affecting the pharmaceutical industry.

U2V2ZXJhbC BzY2VuYXJp b3MgY291bG QgcG90ZW50 aWFsbHkgaW 1wYWlyIFJv eWFsdHkgUG hhcm1h4oCZ cyBlY29ub2 1pY3Mgb3Zl ciB0aGUgbm V4dCAz4oCT NSB5ZWFycy wgYnV0IG9u ZSBwYXJ0aW N1bGFybHkg Y29uY2Vybm luZyBzaXR1 YXRpb24gd2 91bGQgYmUg YSBzaWduaW ZpY2FudCBh bmQgc3VzdG FpbmVkIHJl ZHVjdGlvbi BpbiB0aGUg YXBwcm92YW wgcmF0ZXMg b3Igc2FsZX Mgb2YgZHJ1 Z3MgZm9yIH doaWNoIHRo ZSBjb21wYW 55IGhhcyBh Y3F1aXJlZC Byb3lhbHRp ZXMuIFRoaX MgY291bGQg YmUgY2F1c2 VkIGJ5IGEg Y29tYmluYX Rpb24gb2Yg ZmFjdG9ycy BzdWNoIGFz IHJlZ3VsYX RvcnkgY2hh bmdlcywgaW 5jcmVhc2Vk IGNvbXBldG l0aW9uIGZy b20gZ2VuZX JpY3MsIGEg c2xvd2Rvd2 4gaW4gdGhl IGRydWcgZG V2ZWxvcG1l bnQgcGlwZW xpbmUsIG9y IGEgbWFqb3 IgcHVibGlj IGhlYWx0aC BjcmlzaXMg dGhhdCBzaG lmdHMgZm9j dXMgYW5kIG Z1bmRpbmcg YXdheSBmcm 9tIGNlcnRh aW4gdGhlcm FwZXV0aWMg YXJlYXMuID xicj5JbiB0 aGlzIHNjZW 5hcmlvLCB0 aGUgY29tcG FueeKAmXMg bWFyZ2lucy Bjb3VsZCBl eHBlcmllbm NlIGEgc2hh cnAgZGVjbG luZSBkdWUg dG8gZGVjcm Vhc2VkIHJv eWFsdHkgcm V2ZW51ZXMs IGxlYWRpbm cgdG8gbG93 ZXIgcHJvZm l0YWJpbGl0 eS4gVGhlIH JlZHVjZWQg c2FsZXMgd2 91bGQgZGly ZWN0bHkgaW 1wYWN0IGNh c2ggZmxvdy wgY2F1c2lu ZyBhIHBvdG VudGlhbCBj YXNoIGNydW 5jaC4gSWYg dGhlIGNvbX BhbnkgcmVs aWVzIGhlYX ZpbHkgb24g cmVmaW5hbm Npbmcgb3Ig bmV3IGRlYn QgdG8gc3Vz dGFpbiBpdH Mgb3BlcmF0 aW9ucyBkdX JpbmcgdGhp cyBkb3dudH VybiwgaXQg bWlnaHQgcm VzdWx0IGlu IGEgaGVhdm llciBmaW5h bmNpYWwgYn VyZGVuLCBp bmNyZWFzaW 5nIGludGVy ZXN0IGV4cG Vuc2VzIGFu ZCBsaW1pdG luZyBpbnZl c3RtZW50cy BpbiBmdXR1 cmUgcHJvam VjdHMuPGJy PlRoZSBiYW xhbmNlIHNo ZWV0IHdvdW xkIGxpa2Vs eSByZWZsZW N0IGEgd2Vh a2VuZWQgcG 9zaXRpb24s IHdpdGggcG 90ZW50aWFs IGFzc2V0IG ltcGFpcm1l bnRzIHJlbG F0ZWQgdG8g cm95YWx0eS BhZ3JlZW1l bnRzIHRoYX QgYXJlIHVu ZGVycGVyZm 9ybWluZyBv ciBoYXZlIG 5vdCBtZXQg dGhlIGFudG ljaXBhdGVk IHJlZ3VsYX RvcnkgYXBw cm92YWwgdG ltZWxpbmVz LiBJbmNyZW FzZWQgbGV2 ZXJhZ2UgZH VlIHRvIHJp c2luZyBkZW J0IGxldmVs cyBjb3VsZC BkZXRlcmlv cmF0ZSBmaW 5hbmNpYWwg cmF0aW9zLC BtYWtpbmcg aXQgaGFyZG VyIGZvciBS b3lhbHR5IF BoYXJtYSB0 byByYWlzZS BhZGRpdGlv bmFsIGNhcG l0YWwgb3Ig aW52ZXN0IG luIG5ldyBv cHBvcnR1bm l0aWVzLjxi cj5PdmVyYW xsLCB0aGUg Y29tYmluYX Rpb24gb2Yg ZGltaW5pc2 hlZCByZXZl bnVlIHN0cm VhbXMsIHRp Z2h0ZW5lZC BtYXJnaW5z LCBjb25zdH JhaW5lZCBj YXNoIGZsb3 csIGFuZCBh IHBvdGVudG lhbGx5IHdl YWtlciBiYW xhbmNlIHNo ZWV0IGNvdW xkIHBvc2Ug c2VyaW91cy Bsb25nLXRl cm0gY2hhbG xlbmdlcyBm b3IgUm95YW x0eSBQaGFy bWHigJlzIG J1c2luZXNz IG1vZGVsIG FuZCBzdXN0 YWluYWJpbG l0eSBpbiB0 aGUgbWFya2 V0Ljxicj4=

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQW lIaGVaYjRx bklaOXkzQn UwODAud2Vi cCIgYWx0PS JSb3lhbHR5 IFBoYXJtYS IgdGl0bGU9 IlJveWFsdH kgUGhhcm1h IiAgY2xhc3 M9ImltZy1m bHVpZCIgaG VpZ2h0PTUw IHdpZHRoPT UwIGxvYWRp bmc9J2xhen knIHN0eWxl PSdib3JkZX ItcmFkaXVz OiA2cHg7Jz 4KCiAgICAg ICAgICAgIC AgICAgICAg PGRpdiBzdH lsZT0nZmxl eDogMTsgdG V4dC1hbGln bjogY2VudG VyOyBtYXJn aW4tbGVmdD ogNXB4Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxwIHN0 eWxlPSdmb2 50LXNpemU6 IDI2cHg7IG NvbG9yOiAj MzMzOyBtYX JnaW4tYm90 dG9tOiAxNX B4Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICDwn5OI IFdhbnQgdG 8gcmVhZCBt b3JlIGFib3 V0IFJveWFs dHkgUGhhcm 1hPwogICAg ICAgICAgIC AgICAgICAg ICAgICA8L3 A+CgogICAg ICAgICAgIC AgICAgICAg ICAgICA8YS BocmVmPSdp bmRleC5waH A/cGFnZT1z aWdudXAnIH N0eWxlPScK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJh Y2tncm91bm QtY29sb3I6 ICMwMDdCRk Y7CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Bjb2xvcjog I2ZmZjsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIHBhZG Rpbmc6IDEw cHggMjBweD sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG JvcmRlci1y YWRpdXM6ID VweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHRleHQt ZGVjb3JhdG lvbjogbm9u ZTsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGZvbnQtd2 VpZ2h0OiBi b2xkOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgbWFyZ2 luLXJpZ2h0 OiAxMHB4Ow ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgdH JhbnNpdGlv bjogYmFja2 dyb3VuZC1j b2xvciAwLj NzIGVhc2U7 JwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg b25tb3VzZW 92ZXI9J3Ro aXMuc3R5bG UuYmFja2dy b3VuZENvbG 9yPSIjMDA1 NmIzIicKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIG9ubW 91c2VvdXQ9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA3QkZGIi c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BTaWduIHVw IGZvciBmcm VlCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvYT 4KCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxzcG FuIHN0eWxl PSdtYXJnaW 46IDAgOHB4 OyBjb2xvcj ogIzU1NTsn Pm9yPC9zcG FuPgoKICAg ICAgICAgIC AgICAgICAg ICAgICAgPG EgaHJlZj0n aW5kZXgucG hwP3BhZ2U9 bG9naW4nIH N0eWxlPScK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGNv bG9yOiAjMD A3QkZGOwog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdGV4 dC1kZWNvcm F0aW9uOiB1 bmRlcmxpbm U7CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Bmb250LXdl aWdodDogNT AwOyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBsb2cg aW4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9h PgoKCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxw IHN0eWxlPS dtYXJnaW4t dG9wOiAxNX B4OyBmb250 LXNpemU6ID EzcHg7IGZv bnQtd2VpZ2 h0OiBib2xk OyBjb2xvcj ogI2QzMmYy ZjsnPgogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAg8J+SoS BMZWFybiBz bWFydGVyIH N0b2NrIHBp Y2tzIHdpdG ggPGk+IlRo ZSBDaGVja2 xpc3QgVmFs dWUgSW52ZX N0b3Ig4oCU IEEgU21hcn RlciBXYXkg dG8gUGljay BTdG9ja3Mi PC9pPgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 L3A+CgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 IS0tCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxk aXYgc3R5bG U9J21hcmdp bi10b3A6ID EycHg7IGZv bnQtc2l6ZT ogMTNweDsg Y29sb3I6IC M0NDQ7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIFNp Z24gdXAgbm 93IGFuZCBn ZXQgb3VyIG ZyZWUgZUJv b2sgCiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8Yj5UaG UgQ2hlY2ts aXN0IFZhbH VlIEludmVz dG9yIOKAlC BBIFNtYXJ0 ZXIgV2F5IH RvIFBpY2sg U3RvY2tzPC 9iPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgLS 0+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwhLS 0KICAgICAg ICAgICAgIC AgICAgICAg ICAgPGRpdi BzdHlsZT0n bWFyZ2luLX RvcDogMTZw eDsgZm9udC 1zaXplOiAx NHB4OyBjb2 xvcjogIzQ0 NDsgZm9udC 1mYW1pbHk6 IC1hcHBsZS 1zeXN0ZW0s IEJsaW5rTW FjU3lzdGVt Rm9udCwgU2 Vnb2UgVUks IFJvYm90by wgSGVsdmV0 aWNhIE5ldW UsIHNhbnMt c2VyaWY7IG xpbmUtaGVp Z2h0OiAxLj Y7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIEhhdmUg eW91IGhlYX JkIGFib3V0 IG91ciBzaG 9ydCA8c3Ry b25nIHN0eW xlPSdmb250 LXdlaWdodD ogNjAwOyc+ RGFpbHkgVm lkZW8gTmV3 c2xldHRlcj wvc3Ryb25n Pj8KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IDxhIGhyZW Y9J2h0dHBz Oi8vd3d3Lm luc2lnaHRm dWx2YWx1ZS 5jb20vbmV3 c2xldHRlci 5waHAnIHRh cmdldD0nX2 JsYW5rJyBz dHlsZT0nY2 9sb3I6ICMw MDdCRkY7IH RleHQtZGVj b3JhdGlvbj ogbm9uZTsg Zm9udC13ZW lnaHQ6IDUw MDsgbWFyZ2 luLWxlZnQ6 IDZweDsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIEZpbmQg b3V0IG1vcm UKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgIDwv ZGl2PgogIC AgICAgICAg ICAKICAgIC AgICAKICAg ICAgICA8c3 BhbiBjbGFz cz0nYmx1cn JlZC10ZXh0 Jz4KICAgIC AgICAgICAg VW05NVlXeD BlUyBCUWFH RnliV0VnIG FYTWdZU0Jz WlcgRmthVz VuSUdsdSBk bVZ6ZEcxbG JuIFFnWm1s eWJTQjAgYU dGMElITnda VyBOcFlXeH BlbVZ6IElH bHVJR0ZqY1 ggVnBjbWx1 WnlCeSBaWF psYm5WbExX IGRsYm1WeV lYUnAgYm1j Z2NHaGhjbS AxaFkyVjFk R2xqIFlXd2 djbTk1WVcg eDBhV1Z6TG lCSSBaWEps SUdGeVpTIE J6YjIxbElH bHUgZEdWeV pYTjBhVyA1 bklHWmhZM1 J6IElHRmli M1YwSUggUm 9aU0JqYjIx dyBZVzU1T2 p4aWNqIDR4 TGlCR2IzVn UgWkdWa0lH bHVJRCBFNU 9UWTZJRkp2 IGVXRnNkSG tnVUcgaGhj bTFoSUhkaC BjeUJsYzNS aFltIHhwYz JobFpDQmkg ZVNCUVlXSn NieSBCTVpX ZHZjbkpsIG RHRWdZVzVr SUcgaGhjeU J6YVc1aiBa U0JuY205M2 JpIEJwYm5S dklHRWcgYz JsbmJtbG1h VyBOaGJuUW djR3hoIGVX VnlJR2x1SU ggUm9aU0Jv WldGcyBkR2 hqWVhKbElH IGx1ZG1Wem RHMWwgYm5R Z2MyVmpkRy A5eUxqeGlj ajR5IExpQk diMk4xY3kg QnZiaUJ5Yj NsaCBiSFJw WlhNNklGIF JvWlNCamIy MXcgWVc1NT RvQ1pjeSBC d2NtbHRZWE o1IElHSjFj Mmx1WlggTn pJRzF2WkdW cyBJSEpsZG 05c2RtIFZ6 SUdGeWIzVn UgWkNCd2RY SmphRyBGem FXNW5JSEp2 IGVXRnNkR2 xsY3kgQm1j bTl0SUhCby BZWEp0WVdO bGRYIFJwWT JGc0lHTnYg YlhCaGJtbG xjeSBCdmJp QnpjR1ZqIG FXWnBZeUJr Y24gVm5jeU IwYUdGMCBJ R0Z5WlNCaG JIIEpsWVdS NUlHOXUgSU hSb1pTQnRZ WCBKclpYUW diM0lnIGFX NGdiR0YwWl MgMXpkR0Zu WlNCayBaWF psYkc5d2JX IFZ1ZEM0OF luSSsgTXk0 Z1VHOXlkRy BadmJHbHZJ R1JwIGRtVn ljMmwwZVQg b2dVbTk1WV d4MCBlU0JR YUdGeWJXIE VnYUdGeklH RWcgWkdsMl pYSnpaUyBC d2IzSjBabT lzIGFXOGdk R2hoZEMgQn BibU5zZFdS bCBjeUJ5Yj NsaGJIIFJw WlhNZ1puSn YgYlNCMllY SnBiMyBWek lIUm9aWEpo IGNHVjFkR2 xqSUcgRnla V0Z6TENCei BkV05vSUdG eklHIDl1WT I5c2IyZDUg TENCdVpYVn liMiB4dloz a3NJR0Z1IF pDQnlZWEps SUcgUnBjMl ZoYzJWeiBM aUJVYUdsek lHIFJwZG1W eWMybG0gYV dOaGRHbHZi aSBCb1pXeH djeUJpIFlX eGhibU5sSU ggSnBjMnN1 UEdKeSBQal F1SUU1dmRH IEZpYkdVZ1 lXTnggZFds emFYUnBiMi A1ek9pQlVh R1VnIFkyOX RjR0Z1ZVMg Qm9ZWE1nYl dGayBaU0J6 YVdkdWFXIF pwWTJGdWRD QmggWTNGMW FYTnBkRyBs dmJuTWdiM1 psIGNpQjBh R1VnZVcgVm hjbk1zSUds dSBZMngxWk dsdVp5IEJ5 YjNsaGJIUn AgWlhNZ2Iy NGdjMiA5dF pTQnZaaUIw IGFHVWdZbV Z6ZEMgMXpa V3hzYVc1bi BJR1J5ZFdk eklHIGx1SU hSb1pTQjMg YjNKc1pDd2 djMyBWamFD QmhjeUJJIG RXMXBjbUVz SUUgVjViR1 ZoTENCaCBi bVFnVm1WeW RHIFY0NG9D WmN5QmogZV hOMGFXTWda bSBsaWNtOX phWE1nIFpI SjFaM011UE cgSnlQalV1 SUVsUSBUem 9nVW05NVlX IHgwZVNCUW FHRnkgYldF Z2QyVnVkQy BCd2RXSnNh V01nIGFXNG dTblZ1WlMg QXlNREl3TE NCeSBZV2x6 YVc1bklHIE Z3Y0hKdmVH bHQgWVhSbG JIa2dKRCBJ Z1ltbHNiR2 x2IGJpQnBi aUJwZEggTW dhVzVwZEds aCBiQ0J3ZF dKc2FXIE1n YjJabVpYSn AgYm1jdUlG Um9hWCBNZ2 JXOTJaU0J5 IFpYQnlaWE 5sYm4gUmxa Q0JoSUhOcC BaMjVwWm1s allXIDUwSU cxcGJHVnog ZEc5dVpTQm 1iMyBJZ2RH aGxJR052IG JYQmhibmtn WVcgNWtJSE J5YjNacCBa R1ZrSUdsME lIIGRwZEdn Z1lXUmsgYV hScGIyNWhi QyBCallYQn BkR0ZzIElI UnZJSEIxY2 4gTjFaU0Jt ZFhKMCBhR1 Z5SUdGamNY IFZwYzJsMG FXOXUgY3k0 OFluSStOaS A0Z1VHRnlk RzVsIGNuTm 9hWEJ6SUgg ZHBkR2dnWW 1sdiBkR1Zq YUNCbWFYIE p0Y3pvZ1ZH aGwgSUdOdm JYQmhibiBr Z2IyWjBaVz RnIFkyOXNi R0ZpYjMgSm hkR1Z6SUhk cCBkR2dnWW 1sdmRHIFZq YUNCamIyMX cgWVc1cFpY TXNJRyA5bV ptVnlhVzVu IElIUm9aVz BnZEcgaGxJ Rzl3Y0c5eS BkSFZ1YVhS NUlIIFJ2SU cxdmJtVjAg YVhwbElIUm 9aVyBseUlH WjFkSFZ5IF pTQnlaWFps Ym4gVmxJSE 4wY21WaCBi WE1nZDJocG JHIFVnYzNS cGJHd2cgYV c1MlpYTjBh VyA1bklHbH VJSEpsIGMy VmhjbU5vSU cgRnVaQ0Jr WlhabCBiRz l3YldWdWRD IDQ4WW5JK0 55NGcgUm1s dVlXNWphVy BGc0lITjBj bVZ1IFozUm 9PaUJTYjMg bGhiSFI1SU ZCbyBZWEp0 WVNCb1lYIE 1nWkdWdGIy NXogZEhKaG RHVmtJSCBO MGNtOXVaeU JtIGFXNWhi bU5wWVcgd2 djR1Z5Wm05 eSBiV0Z1WT JVc0lHIE52 Ym5OcGMzUm wgYm5Sc2VT Qm5aVyA1bG NtRjBhVzVu IElITjFZbk 4wWVcgNTBh V0ZzSUdOaC BjMmdnWm14 dmR5IHdnZD JocFkyZ2cg Wlc1aFlteG xjeSBCcGRD QjBieUJ5IF pXbHVkbVZ6 ZEMgQnBiaU JoWTNGMSBh WEpwYm1jZ2 JXIDl5WlNC eWIzbGggYk hScFpYTWdZ VyA1a0lISm xkSFZ5IGJp QjJZV3gxWl MgQjBieUJ6 YUdGeSBaV2 h2YkdSbGNu IE11UEdKeV BqZ3UgSUVO dmJXMXBkRy AxbGJuUWdk RzhnIGFXNX ViM1poZEcg bHZiam9nVk dobCBJR052 YlhCaGJuIG 5pZ0pseklH bHUgZG1Wem RHMWxibiBS eklHRnlaU0 JuIFpXRnla V1FnZEcgOT NZWEprY3lC cCBibTV2ZG 1GMGFYIFps SUhSb1pYSm ggY0dsbGN5 d2djMyBWd2 NHOXlkR2x1 IFp5QjBhR1 VnWkcgVjJa V3h2Y0cxbC BiblFnYjJZ Z2JtIFYzSU hSeVpXRjAg YldWdWRITW dkRyBoaGRD QmpZVzRnIG NHOTBaVzUw YVcgRnNiSG tnYVcxdyBj bTkyWlNCd1 lYIFJwWlc1 MElHOTEgZE dOdmJXVnpM aiB4aWNqND VMaUJUIGRI SnZibWNnYk cgVmhaR1Z5 YzJocCBjRG 9nVW05NVlX IHgwZVNCUW FHRnkgYldI aWdKbHpJRy AxaGJtRm5a VzFsIGJuUW dkR1ZoYlMg QnBibU5zZF dSbCBjeUJs ZUhCbGNtIG xsYm1ObFpD QncgY205bV pYTnphVyA5 dVlXeHpJR1 p5IGIyMGdZ bTkwYUMgQm 1hVzVoYm1O cCBZV3dnWV c1a0lIIEJv WVhKdFlXTm wgZFhScFky RnNJRyBKaF kydG5jbTkx IGJtUnpMQ0 IzYUcgbGph Q0J3Y205Mi BhV1JsY3lC aElIIE4wY2 05dVp5Qm0g YjNWdVpHRj BhVyA5dUlH WnZjaUJ0IF lXdHBibWNn YVcgNW1iM0 p0WldRZyBh VzUyWlhOMG JXIFZ1ZENC a1pXTnAgYz JsdmJuTXVQ RyBKeVBqRX dMaUJUIGIy TnBZV3dnY2 0gVnpjRzl1 YzJsaSBhV3 hwZEhrNklG IFJvWlNCam IyMXcgWVc1 NUlHbHpJRy BGc2MyOGdh VzUyIGIyeD JaV1FnYVcg NGdjR2hwYk dGdSBkR2h5 YjNCcFl5IE JsWm1admNu UnogTENCam IyNTBjbSBs aWRYUnBibW NnIGRHOGdj bVZ6WlcgRn lZMmdnWVc1 ayBJR1JsZG 1Wc2IzIEJ0 Wlc1MElHbH UgYVhScFlY UnBkbSBWek lIUm9ZWFFn IGMyVmxheU IwYnkgQmha R1J5WlhOei BJSFZ1YldW MElHIDFsWk dsallXd2cg Ym1WbFpITX VQRyBKeVBs Um9aWE5sIE lHWmhZM1J6 SUcgaHBaMm hzYVdkbyBk Q0JTYjNsaG JIIFI1SUZC b1lYSnQgWW VLQW1YTWdk VyA1cGNYVm xJSEJ2IGMy bDBhVzl1SU cgbHVJSFJv WlNCdyBhR0 Z5YldGalpY IFYwYVdOaG JDQnAgYm5a bGMzUnRaVy A1MElHeGhi bVJ6IFkyRn daU0JoYm0g UWdhWFJ6SU hOMCBjbUYw WldkcFl5IE JoY0hCeWIy RmogYUNCMG J5Qm5aVyA1 bGNtRjBhVz VuIElISmxk bVZ1ZFcgVW dkR2h5YjNW biBhQ0J5Yj NsaGJIIFJw WlhNdVBHSn kgUGc9PQog ICAgICAgID wvc3Bhbj4K ICAgICAgIC AKICAgICAg ICA=